Natural history of dR modified by anti-VEGF treatment

Analysis of patients with diabetic macular oedema (DME) who participated in the RISE and RIDE phase III trials demonstrates that ranibizumab reduces diabetic retinopathy severity in many patients, and can slow the clinical progression of the disease, according to a presentation at the 13th EURETINA Congress.
“These data underscore the need for early screening and appropriate intervention in DME patients, who without treatment are at high risk of developing proliferative diabetic retinopathy,” said Patricio G Schlottmann MD.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.